Financials Brainstorm Cell Therapeutics Inc.
Equities
BCLI
US10501E2019
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5169 USD | -3.80% | -8.84% | +89.34% |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 96.76 | 142.8 | 145.1 | 59.93 | 13.37 | 36.72 | - | - |
Enterprise Value (EV) 1 | 96.76 | 142.8 | 145.1 | 59.93 | 13.37 | 36.72 | 36.72 | 36.72 |
P/E ratio | -4.04 x | -4.23 x | -5.88 x | -2.48 x | -0.68 x | -1.85 x | -1.38 x | -1.25 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 22,606 | 31,568 | 36,278 | 36,542 | 48,982 | 68,342 | - | - |
Reference price 2 | 4.280 | 4.525 | 4.000 | 1.640 | 0.2730 | 0.5169 | 0.5169 | 0.5169 |
Announcement Date | 2/18/20 | 2/4/21 | 3/28/22 | 3/30/23 | 4/1/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - |
EBIT 1 | -23 | -31.68 | -24.54 | -24.82 | -21.44 | -21.9 | -27.43 | -31.1 |
Operating Margin | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -23.25 | -31.81 | -24.46 | -24.28 | -17.19 | -21.9 | -27.43 | -31.1 |
Net income 1 | -23.25 | -31.81 | -24.46 | -24.28 | -17.19 | -21.9 | -27.43 | -31.1 |
Net margin | - | - | - | - | - | - | - | - |
EPS 2 | -1.060 | -1.070 | -0.6800 | -0.6600 | -0.4000 | -0.2800 | -0.3750 | -0.4150 |
Free Cash Flow | - | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 2/18/20 | 2/4/21 | 3/28/22 | 3/30/23 | 4/1/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -6.212 | -5.475 | -7.591 | -6.841 | -4.915 | -5.151 | -5.449 | -6.035 | -4.804 | -2.474 | -5.2 | -5.8 | -6.4 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -6.19 | -5.36 | -7.041 | -6.858 | -5.018 | -5.059 | -5.329 | -1.226 | -5.578 | -3.401 | -5.2 | -5.8 | -6.4 |
Net income 1 | -6.19 | -5.36 | -7.041 | -6.858 | -5.018 | -5.059 | -5.329 | -1.226 | -5.578 | -3.401 | -5.2 | -5.8 | -6.4 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.1700 | -0.1500 | -0.1900 | -0.1900 | -0.1300 | -0.1400 | -0.1300 | -0.0300 | -0.1100 | -0.0500 | -0.0700 | -0.0600 | -0.0700 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/28/22 | 5/16/22 | 8/15/22 | 11/14/22 | 3/30/23 | 5/15/23 | 8/14/23 | 11/14/23 | 4/1/24 | 5/14/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - | - |
Announcement Date | 2/18/20 | 2/4/21 | 3/28/22 | 3/30/23 | 4/1/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+89.34% | 36.72M | |
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |
- Stock Market
- Equities
- BCLI Stock
- Financials Brainstorm Cell Therapeutics Inc.